Blog
RSS FeedPosted by Michael Wonder on 14 Sep 2018
UK ‘less interesting’ to pharma because of Brexit – Roche CEO
14 September 2018 - The UK could be “less interesting” to pharma and life sciences firms after Brexit, the CEO ...
Posted by Michael Wonder on 13 Sep 2018
DoH moves to ensure equal access to cancer drugs in Northern Ireland
13 September 2018 - The Department of Health in Northern Ireland has unveiled plans to boost access to innovative new ...
Posted by Michael Wonder on 11 Sep 2018
ABPI hits out at ‘punitive’ UK medicines cost controls
11 September 2018 - Steep rise in charges an 'alarming signal' amid Brexit uncertainty ...
Posted by Michael Wonder on 11 Sep 2018
Health secretary’s ‘rip off’ remarks anger UK pharma
11 September 2018 - Row with Vertex has tainted government-industry relations. ...
Posted by Michael Wonder on 10 Sep 2018
NICE turns down Opdivo for adjuvant melanoma therapy
10 September 2018 - BMS drug currently only licensed treatment in this setting. ...
Posted by Michael Wonder on 10 Sep 2018
Drug firms try to rip off taxpayers, says Matt Hancock
8 September 2018 - Pharmaceutical companies are trying to “rip off taxpayers” and big business must be more socially responsible, ...
Posted by Michael Wonder on 10 Sep 2018
Roche faces UK pricing row over multiple sclerosis drug Ocrevus
10 September 2018 - Roche faces a fresh row over drug pricing in Britain, following a decision by the body responsible ...
Posted by Michael Wonder on 10 Sep 2018
MS Society launches petition against NICE’s rejection of Ocrevus
10 september 2018 - The MS Society has launched a petition imploring the National Institute for Health and Care Excellence, ...
Posted by Michael Wonder on 06 Sep 2018
UK lags behind most of Europe in access to biologics for patients with rheumatoid arthritis
4 September 2018 - Global leader in biosimilars, Celltrion Healthcare announces support for the easing of initiation boundaries for biologics that ...
Posted by Michael Wonder on 05 Sep 2018
Hand surgeon's career 'saved by gene-silencing drug'
5 September 2018 - Hand surgeon Carlos Heras-Palou said his career "would have been finished" in six months without the treatment. ...
Posted by Michael Wonder on 05 Sep 2018
NICE u-turn approves funding for rare disease therapy Crysvita
5 September 2018 - NICE has changed its position on NHS funding for Kyowa Kirin International’s Crysvita, now endorsing the ...
Posted by Michael Wonder on 05 Sep 2018
Deal for NHS to offer exciting new child cancer therapy
5 September 2018 - A deal has been struck to let the NHS offer children an expensive new cancer therapy ...
Posted by Michael Wonder on 04 Sep 2018
Merck gets partial thumbs-down on Keytruda in lymphoma from NICE cost-effectiveness watchdogs
4 September 2018 - NICE quibbled with Merck's methodology for demonstrating the cost effectiveness of Keytruda in treating Hodgkin lymphoma patients ...
Posted by Michael Wonder on 29 Aug 2018
Cancer charities dismayed after ‘new generation’ therapy rejected as too expensive
29 August 2018 - A NICE committee said the cost of the drug was “too high for it to be considered ...
Posted by Michael Wonder on 29 Aug 2018
Developing tools to support digital health and medtech innovation
8 August 2018 - NICE is involved in two key initiatives with national partners to achieve these aims by developing standards ...